Skip to content

Phase 3 Data

For more information, please contact us.

For more information, please contact us.

Study ATB-203

The REAKT trial (Reltecimod Efficacy for Acute Kidney Injury Trial), is designed to assess the efficacy and safety of Reltecimod versus placebo in patients with SA-AKI.

Interim results for the REAKT study are expected to be available during the first half of 2020.

For more information, please go to https://www.clinicaltrials.gov/ct2/show/NCT03403751?term=atox&rank=2